News Medical

What is the safety of Molnupiravir against SARS-CoV-2 in the elderly?

With lockdown restrictions easing in many countries, coronavirus disease 2019 (COVID-19) is becoming more prevalent among the elderly. Newer variants of concern (VOCs) of the severe acute respiratory ...
News Medical

Study confirms efficacy of molnupiravir against COVID in a real-life cohort

Since the onset of the coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), over 6.38 million deaths and 572 million infections have ...
Business Wire

Merck and Ridgeback’s Molnupiravir Receives U.S. FDA Emergency Use Authorization for the Treatment of High-Risk Adults With Mild to Moderate COVID-19

KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that the U.S. Food and Drug ...
Forbes

Taking A Closer Look At Molnupiravir. Is Continued Use Justified?

This article is part of a larger series on the risks of molnupiravir. For a summary of the risks at the level of the individual, see here, and for an overview of the risks on a societal level, see ...
Business Wire

Merck and Ridgeback to Present Data Demonstrating That Treatment With LAGEVRIO™ (molnupiravir) Was Associated With More Rapid Elimination of Infectious SARS-CoV-2 Than Placebo

KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that data evaluating LAGEVRIO™ ...
Forbes

UK Approval Of Molnupiravir May Create New And More Dangerous Covid-19 Variants

As of this morning, British drug regulators have approved the Covid-19 antiviral drug molnupiravir for use in Covid-19 patients at risk for severe illness, making them the first public health ...
The Conversation

Molnupiravir: why are there potential safety issues around this COVID antiviral?

If you’re worried about COVID, there’s a simple way to boost protection: get vaccinated. But this doesn’t work for everyone. People with weak immune systems – perhaps because of age or a medical ...
Medical Xpress

Analysis finds additional clinical benefits of molnupiravir for nonhospitalized participants with COVID-19

A secondary analysis of the randomized controlled MOVe-OUT trial found additional clinical benefits of molnupiravir for nonhospitalized participants with mild to moderate COVID-19 and risk factors for ...
Monthly Prescribing Reference

FDA Authorizes Use of Oral Antiviral Molnupiravir for Mild to Moderate COVID-19

Credit: Merck. The EUA was supported by data from the phase 3 MOVe-OUT trial, which compared the efficacy and safety of molnupiravir to placebo in 775 nonhospitalized adults with symptom onset within ...
Monthly Prescribing Reference

Molnupiravir Misses Endpoint in COVID-19 Prevention Study

Credit: Merck. The MOVe-AHEAD study enrolled over 1500 participants 18 years of age and older who resided in the same household with someone who tested positive for SARS-CoV-2. Results were announced ...
CNBC

FDA advisory panel narrowly endorses Merck's oral Covid treatment pill, despite reduced efficacy and safety questions

The FDA's Antimicrobial Drugs Advisory Committee voted 13 to 10 to recommend emergency authorization of molnupiravir. Molnupiravir is an oral antiviral drug designed to treat adults with mild to ...
Nasdaq

Merck and Ridgeback Announce Submission of Emergency Use Authorization Application to the U.S. FDA for Molnupiravir, an Investigational Oral Antiviral Medicine, for the ...

KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that Merck has submitted an Emergency ...